Cargando…

Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report

BACKGROUND: Hypercontractile esophagus is a rare hypercontractile esophageal motility disorder. The etiology of hypercontractile esophagus is unknown but an association between acid reflux and hypercontractile esophagus has been suggested. We present the first report on the use of potassium-competit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Yuyang, Xie, Chen, Feng, Huang, Yan, Donglin, Chen, Weichang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9229428/ https://www.ncbi.nlm.nih.gov/pubmed/35739486 http://dx.doi.org/10.1186/s12876-022-02375-x

Ejemplares similares

Hypercontractile Esophagus With Atypical Symptoms
por: Choi, Yoon Jin, et al.
Publicado: (2014)

The hypercontractile esophagus: Still a tough nut to crack
por: Savarino, Edoardo, et al.
Publicado: (2020)

Two Distinct Types of Hypercontractile Esophagus: Classic and Spastic Jackhammer
por: Hong, Yun Soo, et al.
Publicado: (2016)

Pathophysiology of Potassium-competitive Acid Blocker–refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
por: Masaoka, Tatsuhiro, et al.
Publicado: (2018)

Hypercontractile Esophagus: Clinical and Manometric Features From a Multicenter Korean Cohort
por: Min, Yang Won, et al.
Publicado: (2023)

Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022)

Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
por: Luo, Hua-Jun, et al.
Publicado: (2014)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
por: Zhou, Sufeng, et al.
Publicado: (2023)

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
por: Rawla, Prashanth, et al.
Publicado: (2018)

Gastric polyps' regression after potassium‐competitive acid blocker cessation
por: Iwamuro, Masaya, et al.
Publicado: (2022)

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023)

Airway Smooth Muscle Hypercontractility in Asthma
por: Berair, Rachid, et al.
Publicado: (2013)

Distribution- and Metabolism-Based Drug Discovery: A Potassium-Competitive Acid Blocker as a Proof of Concept
por: Wang, Ming-Shu, et al.
Publicado: (2022)

Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases
por: Oshima, Tadayuki, et al.
Publicado: (2018)

Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan
por: Okamoto, Masaru, et al.
Publicado: (2021)

Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker
por: Mori, Hideki, et al.
Publicado: (2019)

Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?
por: Hunt, Richard H, et al.
Publicado: (2015)

Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori
por: Yamada, Shinya, et al.
Publicado: (2016)

JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
por: Ku, Jin Mo, et al.
Publicado: (2023)

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
por: Son, Mijeong, et al.
Publicado: (2022)

Smooth Muscle Hypercontractility in Airway Hyperresponsiveness: Innate, Acquired, or Nonexistent?
por: Bossé, Ynuk, et al.
Publicado: (2013)

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review
por: Domingues, Gerson, et al.
Publicado: (2022)

Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
por: Cho, Yu Kyung, et al.
Publicado: (2020)

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020)

Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
por: Sue, Soichiro, et al.
Publicado: (2021)

Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations
por: Spudich, James A.
Publicado: (2019)

Nippostrongylus-Induced Intestinal Hypercontractility Requires IL-4 Receptor Alpha-Responsiveness by T Cells in Mice
por: Schmidt, Saskia, et al.
Publicado: (2012)

Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
por: Ashida, K., et al.
Publicado: (2015)

Treatment strategies for reflux esophagitis including a potassium‐competitive acid blocker: A cost‐effectiveness analysis in Japan
por: Habu, Yasuki, et al.
Publicado: (2021)

A Novel Variant in TPM3 Causing Muscle Weakness and Concomitant Hypercontractile Phenotype
por: Robaszkiewicz, Katarzyna, et al.
Publicado: (2023)

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
por: Sugano, Kentaro
Publicado: (2018)

Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
por: Lee, Kwang Jae, et al.
Publicado: (2019)

Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth
por: Kim, Ji Yeon, et al.
Publicado: (2021)

Prediction of effectiveness of potassium-competitive acid blocker and serotonin noradrenaline reuptake inhibitor on abnormal sensation in the throat: use of patient-reported outcome measures (PROMs)
por: Takahashi, Nao, et al.
Publicado: (2021)

Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia
por: Asaoka, Daisuke, et al.
Publicado: (2017)

Regulation of Myosin Light-Chain Phosphatase Activity to Generate Airway Smooth Muscle Hypercontractility
por: Álvarez-Santos, Mayra D., et al.
Publicado: (2020)

A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis
por: Simadibrata, Daniel Martin, et al.
Publicado: (2022)

Histamine2-Receptor Antagonists, Proton Pump Inhibitors, or Potassium-Competitive Acid Blockers Preventing Delayed Bleeding After Endoscopic Submucosal Dissection: A Meta-Analysis
por: Jiang, Xin, et al.
Publicado: (2019)

Aminoguanidine inhibits aortic hydrogen peroxide production, VSMC NOX activity and hypercontractility in diabetic mice
por: Oak, Jeong-Ho, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_n9thl56bq9cn84jpi265mitiht